Colinz Laboratories Ltd. engages in the manufacture of pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, injectable, ointments, and creams. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2004-01-13. The firm operates and supplies medicines in the domestic market. The Company’s products include oncology, ayurvedic and nutraceuticals. Its oncology products include imatinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, doxorubicin, filgrastim and pegylated liposome doxorubicin. Its ayurvedic products include anti-diarrheas, anti-pyrectics, anti-inflammatories, anti-spasmodic, cough syrups, appetite stimulating agents, memory boosters, anti-piles, antacids, liver tonic, ulcer healing agents, digestive agents, drugs to treat oligospermia and erectile dysfunction, ear drops, uterine tonic, anti-diabetics, and general tonics.
Loading chart…
Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:
The headline call - descriptive label, conviction, and the synthesis behind it.
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Forensic and governance risk pointers, severity-ranked.
Solvency and earnings-quality score.
Quarter-by-quarter earnings-call briefs - what changed and why.